Phase I study of nab-paclitaxel and gemcitabine CRT for BR and UR-LA PDAC
Phase 1
- Conditions
- Borderline resectable or locally advanced unresectable pancreatic cancerPancreatic cancer
- Registration Number
- JPRN-jRCTs041180147
- Lead Sponsor
- Kishiwada Masashi
- Brief Summary
The RD of nab-paclitaxel in our GnP-CRT protocol was 100 mg/m2 with gemcitabine 600 mg/m2 and 3-dimensional conformal radiotherapy to a total dose of 50.4 Gy/28 fr for patients with locally advanced PDAC.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
The cases who were diagnosed as Borderline resectable or locally advanced unresectable pancreatic cancer by MDCT and was histologically diagnosed as malignancy/adenocarcinoma by EUS-FNA or cytology of pancreatic juice
Exclusion Criteria
The patients who have the allergy of medication or severe infection
The patients who was considered to be inappropriate for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method